Compare Fox Corp Class B (FOX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Recursion Pharmaceuticals Inc — how do they compare? Fox Corp Class B trades at $55.89 (market cap $25.36B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Fox Corp Class B is far larger — about 11.9× Recursion Pharmaceuticals Inc's market cap, and Fox Corp Class B pays a 1.02% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| FOX | RXRX | |
|---|---|---|
Market Cap | $25.36B | $2.14B |
Volume | 886,620 | 30,789,535 |
Sector | Media | Health |
52-Week High | $67.76 | $6.79 |
52-Week Low | $44.39 | $2.84 |
Typical Hold Time | 75 Days | 23 Days |
Enterprise Value | $28.72B | $1.66B |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX stock trades at $55.89, down 0.16% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.79 surpassing the $1.44 estimate. Revenue grew to $16.30 billion in 2025, and net income margin improved to 13.88%. Analysts maintain a consensus price target of $84.75, implying significant upside, with 42% recommending Buy.
The outlook is positive given earnings momentum and reasonable valuation multiples, but risks include projected net cash flow turning negative in 2026 and competitive pressures in media. Investor sentiment is supported by bullish analyst targets, though attention is needed on debt levels and future profitability trends.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
